Indication
Treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediatric patients (aged ≥ 6 months) when: • The patient’s influenza virus is known or suspected to be resistant to anti-influenza medicinal products other than zanamivir, and/or • Other anti-viral agents for treatment of influenza, including inhaled zanamivir, are not suitable for the individual patient.

Medicine details

Medicine name:
zanamivir (Dectova)
SMC ID:
SMC2204
Pharmaceutical company
GlaxoSmithKline UK Ltd
BNF chapter
Submission type
Abbreviated
Status
Publication due date:
09 September 2019
SMC meeting date:
06 August 2019
Patient group submission deadline:
TBC